Search bioRxiv⌕ Search

Biology subjects

Navamajiti, N.

Publications and source records attributed to Navamajiti, N..

2 recordsLinked to original sources

Mapping active cis-regulatory elements from transcription initiation events

Determining the activity of cis-regulatory elements (CREs) is essential for modeling gene regulation and interpreting genetic variation. Yet, current methods often lack the specificity to distinguish active regulation from permissive chromatin, the sensitivity to detect unstable enhancer RNAs, or the scalability required to profile limited input material and primary cells. Here, we introduce nucCAGE, a transcription start site (TSS) assay for profiling nuclear, capped RNAs, and PRIME, a computational framework for identifying active CREs from TSS data. Together, these methods increase sensitivity to low-abundance RNAs and enable robust detection of active regulatory elements across diverse contexts. Across multiple orthogonal functional and genetic benchmarks, including fine-mapped eQTLs, ClinVar variants, GWAS loci, and CRISPRi-tested elements, nucCAGE-derived PRIME predictions achieve superior recall compared to state-of-the-art methods while maintaining strong enrichment for phenotype-associated variation. Applying PRIME to the FANTOM5 dataset yields a comprehensive, cell-type-resolved atlas of active CREs that recapitulates known tissue-trait relationships. We demonstrate how this atlas can be used to nominate causal noncoding variants, linking immune-cell enhancer regulation of SMAD3 to asthma and NCOR2 to premature separation of placenta. Together, nucCAGE and PRIME provide a framework for high-sensitivity genome-wide discovery of active CREs and a resource for variant-to-function studies.

genomics↗

Computationally guided high-throughput design of self-assembling drug nanoparticles

Nanoformulations are transforming our capacity to effectively deliver and treat a myriad of conditions. However, many nanoformulation approaches still suffer from high production complexity and low drug loading. One potential solution relies on harnessing co-assembly of drugs and small molecular excipients to facilitate nanoparticle formation through solvent exchange without the need for chemical synthesis, generating nanoparticles with up to 95% drug loading. However, there is currently no understanding which of the millions of possible combinations of small molecules can result in the formation of these nanoparticles. Here we report the development of a high-throughput screening platform coupled to machine learning to enable the rapid evaluation of such nanoformulations. Our platform identified 101 novel self-assembling drug nanoparticles from 2.1 million pairings derived from 788 candidate drugs with one of 2686 excipients, spanning treatments for multiple diseases and often harnessing well-known food additives, vitamins, or approved drugs as carrier materials - with potential for accelerated approval and translation. Given their long-term stability and potential for clinical impact, we further characterize novel sorafenib-glycyrrhizin and terbinafine-taurocholic acid nanoparticles ex vivo and in vivo. We anticipate that this platform could accelerate the development of safer and more efficacious nanoformulations with high drug loadings for a wide range of therapeutics.

bioengineering↗